NeuTrace acquired by Anumana
NeuTrace acquired by Anumana
NeuTrace™
AI/ML driven cardiovascular solutions for Cardiac Electrophysiology
Rooted in deep data science, NeuTrace™ is building solutions for the Cardiac Electrophysiology (EP) community by advancing research, diagnosis, and treatment for patients with abnormal heart rhythms.
Our solutions are driven by proprietary Artificial Intelligence (AI) and Machine Learning (ML) engines. Founded by a team of globally recognized clinicians, scientists, engineers, and AI experts, we are developing innovative solutions for the treatment of heart disease, by combining medical device, clinical and Silicon Valley technology expertise.
With safety, efficiency and efficacy at the heart of our mission, we aim to transform long-term outcomes in cardiovascular conditions by leveraging previously unleveraged data and analytical methods. NeuTrace is a subsidiary of NeuCures, Inc.
NeuFera™
Small molecule therapeutics for cardiovascular diseases
NeuFera™ is pioneering small-molecule therapeutics with a potential to transform the lives of heart-failure patients, by fundamentally improving the current treatment paradigms. We aim for our first-in-class medicines to improve the quality of life, reduce lifetime dependence on daily medication, and extend survival of patients with chronic cardiovascular conditions.
Our therapeutics target the underlying cause of cardiac decline by inhibiting the factors that accelerate heart failure progression.
Led by a team of thought-leaders in cardiology, our team is leveraging our years of research and novel understanding of the role of the nervous system in the pathophysiology of cardiovascular conditions to advance novel scientific pathways.
NeuFera is a subsidiary of NeuCures, Inc.
NeuFera™ is pioneering small-molecule therapeutics with a potential to transform the lives of heart-failure patients, by fundamentally improving the current treatment paradigms. We aim for our first-in-class medicines to improve the quality of life, reduce lifetime dependence on daily medication, and extend survival of patients with chronic cardiovascular conditions.
Our therapeutics target the underlying cause of cardiac decline by inhibiting the factors that accelerate heart failure progression.
Led by a team of thought-leaders in cardiology, our team is leveraging our years of research and novel understanding of the role of the nervous system in the pathophysiology of cardiovascular conditions to advance novel scientific pathways.
NeuFera is a subsidiary of NeuCures, Inc.
